A Randomized, Double-Blind, Placebo-Controlled Single-Ascending-Dose Study to Identify a Subperceptual Dose of Psilocybin in Healthy Adults

Paper. Levy-Cooperman N, Sellers E, Glue P et al.. Pharmaceuticals, 21 Sep 2026.

Tags: Human, RCT, Psilocybin, Anxiety.

Weekly Science Digest, 26 Sep 2026 to 2 Oct 2026, finding 1: Can you get the effect without the trip?

A single psilocybin dose raised sociability in autism-model mice even when given under anaesthesia.

In Cntnap2-knockout mice the effect was durable; isogenic controls showed no change. Separately, a phase 1 study in 56 healthy adults mapped psilocybin from 0.5 to 4.0 mg, finding dose-proportional psilocin exposure, placebo-comparable adverse events and somnolence as the main signal — a defined subperceptual range.

Read the original

—
Node—
Statuslive
Throughput—